REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients

REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.

FDA Approves First Drug Meant to Ease Alzheimer's-Linked Agitation

Medicare coverage debates amplify as FDA approves Rexulti for

Alarm as FDA fast-tracks first antipsychotic drug for agitation in

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

Important News for Older Adults: FDA Approves First Drug to Treat

Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti

FDA advisors to weigh use of Rexulti for Alzheimer's agitation

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

These highlights do not include all the information needed to use

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation